A new pharmacotherapy approach in managing type 2 diabetes mellitus (T2DM) suggests using a combination of GLP-1 receptor agonists and SGLT2 inhibitors for patients who have T2DM along with nonalcoholic fatty liver disease (NAFLD) and a considerable cardiovascular risk [146,147]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.